Xarelto®:
Extensive Global Experience

- More than 15 million patients in clinical practice worldwide across all indications[1]
- Currently investigated in 90 ongoing worldwide clinical trials and real-world setting, with projected enrolments of over 441,000 patients[2]

#1 dispensed NOAC in Canada[3]

Xarelto® is indicated for the:

- treatment of venous thromboembolic events (deep vein thrombosis [DVT], pulmonary embolism [PE]) and prevention of recurrent DVT and PE.
- prevention of stroke and systemic embolism in patients with atrial fibrillation, in whom anticoagulation is appropriate.
- prevention of venous thromboembolic events (VTE) in patients who have undergone elective total hip replacement (THR) or total knee replacement (TKR) surgery.

For the treatment of VTE, Xarelto® is **not** recommended as an alternative to unfractionated heparin in patients with acute pulmonary embolus who are haemodynamically unstable, or who may receive thrombolysis or pulmonary embolectomy, since the safety and efficacy of Xarelto® have not been established in these clinical situations.

Xarelto® is not recommended for use in children less than 18 years of age.

Consult the Xarelto® Product Monograph at http://bayer.ca/xarelto for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The product monograph is also available by calling 1-800-265-7382.

References: 1. Data on file. Bayer Inc. **2.** ClinicalTrials.gov. Last accessed July 28, 2015. **3.** IMS Brogan Canadian Compuscript (TRx) for the two-year period ended January 2016. **4.** Xarelto® (rivaroxaban tablet) Product Monograph. Bayer Inc. July 20, 2015.

Xarelto® rivaroxaban tablet